Table 1.
Prevalence of vaccine serotypes in the PCV pre- and post-uptake time periods
|
No. (%) of isolates of vaccine serotype† |
|||
|---|---|---|---|
|
PCV* |
Pre-uptake |
Post-uptake |
P‡ |
|
PCV13-Prevnar |
128 (62) |
130 (66) |
0.523 |
|
PCV10-Synflorix |
111 (54) |
103 (52) |
0.784 |
|
PCV10-Pneumosil |
112 (55) |
121 (61) |
0.202 |
|
Total |
205 |
197 |
|
*PCV13-Prevnar (Pfizer) covers serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F; PCV10-Synflorix (GSK) covers serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F; PCV10-Pneumosil (Serum Institute of India) covers serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F and 23F.
†The pre- and post-uptake time periods were defined as in Fig. 1.
‡Test that the vaccine serotype proportion is equal in the pre- and post-uptake period.